{
    "eid": "2-s2.0-85110201901",
    "title": "Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)",
    "cover-date": "2021-07-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Biotechnology",
            "@code": "1305",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Konstantinos Syrigos",
        "Istvan Abert",
        "Zoran Andric",
        "Igor N. Bondarenko",
        "Mikhail Dvorkin",
        "Kristina Galic",
        "Rinat Galiulin",
        "Vladimer Kuchava",
        "Virote Sriuranpong",
        "Dmytro Trukhin",
        "Edvard Zhavrid",
        "Dongyue Fu",
        "Laurent M. Kassalow",
        "Stephanie Jones",
        "Zahid Bashir"
    ],
    "citedby-count": 12,
    "ref-count": 33,
    "ref-list": [
        "Cancer statistics, 2021",
        "A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer",
        "Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",
        "Immune checkpoint inhibitors in advanced non\u2013small cell lung cancer",
        "Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art",
        "Personalised medicine for nonsmall cell lung cancer",
        "Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy",
        "Tumor angiogenesis: therapeutic implications",
        "Tumor angiogenesis",
        "Angiogenesis inhibitors in NSCLC",
        "Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab",
        "Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer",
        "Avastin (Bevacizumab) Information",
        "Non-small cell lung cancer: NCCN Evidence Blocks\u2122",
        "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)",
        "The economics of biosimilars",
        "Tracking the price of existing biologics when drugs enter the market",
        "Biosimilars action plan: Balancing innovation and competition",
        "Bevacizumab biosimilars: scientific justification for extrapolation of indications",
        "Five-year lung cancer survival",
        "PF-06439535 (a Bevacizumab biosimilar) compared with reference bevacizumab (Avastin(\u00ae)), both plus paclitaxel and carboplatin, as first-line treatment for advanced non-squamous non-small-cell lung cancer: a randomized, double-blind study",
        "Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): a randomized, double-blind, phase III study"
    ],
    "affiliation": [
        {
            "affiliation-city": "Reading",
            "@id": "60112082",
            "affilname": "TranScrip Partners LLP",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60112082",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Athens",
            "@id": "60069142",
            "affilname": "Athens General Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069142",
            "affiliation-country": "Greece"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Cambridge",
            "@id": "60004219",
            "affilname": "AstraZeneca",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60004219",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Dorset",
            "@id": "126573176",
            "affilname": "Pharmora Solutions",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126573176",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Dnipro",
            "@id": "126572502",
            "affilname": "Komunalnyi zaklad Miska bahatoprofilna klinichna likarnia #4",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126572502",
            "affiliation-country": "Ukraine"
        },
        {
            "affiliation-city": "Odessa",
            "@id": "126572464",
            "affilname": "Odeskyi oblasnyi onkolohichnyi dyspanser",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126572464",
            "affiliation-country": "Ukraine"
        },
        {
            "affiliation-city": "Heves",
            "@id": "126570823",
            "affilname": "M\u00e1trai Gy\u00f3gyint\u00e9zet-Bronchol\u00f3gia",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126570823",
            "affiliation-country": "Hungary"
        },
        {
            "affiliation-city": "Minsk Region",
            "@id": "126570749",
            "affilname": "State Institution N.N. Alexandrov Republican Scientific",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126570749",
            "affiliation-country": "Belarus"
        },
        {
            "affiliation-city": "Cambridge",
            "@id": "126570469",
            "affilname": "Centus Biotherapeutics",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126570469",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Omsk",
            "@id": "119837626",
            "affilname": "Clinical Oncology Dispensary",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/119837626",
            "affiliation-country": "Russian Federation"
        },
        {
            "affiliation-city": "Omsk",
            "@id": "116138516",
            "affilname": "State Budgetary Healthcare Institution of Omsk Region",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/116138516",
            "affiliation-country": "Russian Federation"
        },
        {
            "affiliation-city": "Mostar",
            "@id": "113521739",
            "affilname": "University Clinical Hospital Mostar",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/113521739",
            "affiliation-country": "Bosnia and Herzegovina"
        },
        {
            "affiliation-city": "Belgrade",
            "@id": "112812704",
            "affilname": "Clinical Hospital Center Bezanijska Kosa",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/112812704",
            "affiliation-country": "Serbia"
        },
        {
            "affiliation-city": "Tbilisi",
            "@id": "101407268",
            "affilname": "Institute of Clinical Oncology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/101407268",
            "affiliation-country": "Georgia"
        }
    ],
    "funding": [
        "Centus Biotherapeutics",
        "AstraZeneca"
    ]
}